Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
Key claim: The FDA is classifying simple point-of-care devices that directly detect SARS-CoV-2 viral targets from clinical specimens in near-patient settings into Class II (special controls) to assure safety and effectiveness while reducing regulatory burdens.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the simple point-of-care device to directly detect SARS-CoV-2 viral targets from clinical specimens in near-patient settings into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the simple point-of-care device to directly detect SARS-CoV-2 viral targets from clinical specimens in near-patient settings. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
Classifying simple point-of-care SARS-CoV-2 detection devices as Class II with special controls establishes a permanent, less burdensome regulatory pathway beyond emergency use authorizations, which affects how quickly manufacturers can bring near-patient COVID diagnostics to clinics, pharmacies, and other non-lab settings. For patients and providers, this shapes availability and turnaround of on-site testing outside traditional laboratory workflows.